MPXOF (MPX International) Equity-to-Asset: 0.15 (As of Mar. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MPX International Equity-to-Asset?

MPX International MPXOF -99.00% Equity-to-Asset is 0.15 as of Mar. 2022.

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. MPX International's Total Stockholders Equity for the quarter that ended in Mar. 2022 was $5.48 Mil. MPX International's Total Assets for the quarter that ended in Mar. 2022 was $37.23 Mil. Therefore, MPX International's Equity to Asset Ratio for the quarter that ended in Mar. 2022 was 0.15.

The historical rank and industry rank for MPX International's Equity-to-Asset or its related term are showing as below:

MPXOF's Equity-to-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.61
* Ranked among companies with meaningful Equity-to-Asset only.

MPX International  (OTCPK:MPXOF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

MPX International Equity-to-Asset Related Terms

MPX International Equity-to-Asset Historical Data

* Premium members only.

The historical data trend for MPX International's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MPX International Equity-to-Asset Chart

MPX International Annual Data
Trend Sep18 Sep19 Sep20 Sep21
Equity-to-Asset
0.96 0.90 0.65 0.35

MPX International Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.52 0.35 0.29 0.15

MPXOF vs ZTS, CTLT, VTRS: Equity-to-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, MPX International's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MPX International Equity-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MPX International's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where MPX International's Equity-to-Asset falls into.


MPX International Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

MPX International's Equity to Asset Ratio for the fiscal year that ended in Sep. 2021 is calculated as

Equity to Asset (A: Sep. 2021 )=Total Stockholders Equity/Total Assets
=13.793/39.989
=0.34

MPX International's Equity to Asset Ratio for the quarter that ended in Mar. 2022 is calculated as

Equity to Asset (Q: Mar. 2022 )=Total Stockholders Equity/Total Assets
=5.478/37.23
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Equity-to-Asset →
What does a Equity-to-Asset of 0.15 mean?
MPX International (MPXOF) has a Equity-to-Asset of 0.15 as of Mar. 2022. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on MPX International and its competitors.
Is MPX International's Equity-to-Asset too high?
MPX International's current Equity-to-Asset is 0.15. The Drug Manufacturers industry median Equity-to-Asset is 0.61. MPX International's value of 0.15 is 75.4% below this industry median.
How does MPX International's Equity-to-Asset compare to ZTS and CTLT?
MPX International's Equity-to-Asset of 0.15 can be compared against companies in the Drug Manufacturers industry. The industry median Equity-to-Asset is 0.61. MPX International's value of 0.15 is 75.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MPX International's current Equity-to-Asset of 0.15 is 75.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on MPX International and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MPX International's current Equity-to-Asset is 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MPX International stock overvalued right now?
MPX International (MPXOF) has a current Equity-to-Asset of 0.15. The current Equity-to-Asset is 0.15 and 75.4% below the Drug Manufacturers industry median of 0.61. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For MPX International (MPXOF), the current Equity-to-Asset is 0.15 as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MPX International Business Description

Address 5255 Yonge Street, Suite 701, Toronto, ON, CAN, M2N 6P4
MPX International Corp is a diversified cannabis company focused on developing and operating assets across the global medical and adult use and engaged in cultivating, manufacturing and marketing products that include cannabinoids as their primary active ingredient. The firm is organized into three segments: Canada, Europe/Africa, and Asia-Pacific. The Canada operating segment's principal business activities consist of production and sale of cannabis, video learning and engagement, patient counselling and referral services. The Europe/Africa operating segment's consist of the production and sale of cannabis and hemp-related products. The Asia-Pacific consist of the production and sale of cannabis. The majority of the revenue is generated in Canada.